Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Long-Term Investments: 2014-2023

Historic Long-Term Investments for ImmunityBio (IBRX) over the last 10 years, with Dec 2023 value amounting to $891,000.

  • ImmunityBio's Long-Term Investments rose 6.07% to $891,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $891,000, marking a year-over-year increase of 6.07%. This contributed to the annual value of $891,000 for FY2023, which is 6.07% up from last year.
  • As of FY2023, ImmunityBio's Long-Term Investments stood at $891,000, which was up 6.07% from $840,000 recorded in FY2022.
  • In the past 5 years, ImmunityBio's Long-Term Investments registered a high of $9.3 million during FY2019, and its lowest value of $822,000 during FY2021.
  • For the 3-year period, ImmunityBio's Long-Term Investments averaged around $851,000, with its median value being $840,000 (2022).
  • In the last 5 years, ImmunityBio's Long-Term Investments rose by 8.86% in 2019 and then crashed by 89.53% in 2021.
  • Over the past 5 years, ImmunityBio's Long-Term Investments (Yearly) stood at $9.3 million in 2019, then dropped by 15.17% to $7.8 million in 2020, then tumbled by 89.53% to $822,000 in 2021, then grew by 2.19% to $840,000 in 2022, then increased by 6.07% to $891,000 in 2023.